Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lifted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 9.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 250,000 shares of the biopharmaceutical company’s stock after purchasing an additional 22,500 shares during the quarter. Ocular Therapeutix comprises about 1.3% of Affinity Asset Advisors LLC’s holdings, making the stock its 17th biggest position. Affinity Asset Advisors LLC’s holdings in Ocular Therapeutix were worth $3,545,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Ocular Therapeutix during the first quarter worth approximately $262,000. Sei Investments Co. lifted its position in Ocular Therapeutix by 34.1% during the 1st quarter. Sei Investments Co. now owns 75,250 shares of the biopharmaceutical company’s stock worth $1,476,000 after acquiring an additional 19,130 shares during the period. Castleark Management LLC increased its stake in shares of Ocular Therapeutix by 48.7% during the first quarter. Castleark Management LLC now owns 485,837 shares of the biopharmaceutical company’s stock worth $7,973,000 after acquiring an additional 159,195 shares during the period. Brown Advisory Inc. acquired a new position in shares of Ocular Therapeutix during the 1st quarter worth $1,477,000. Finally, Swiss National Bank increased its holdings in Ocular Therapeutix by 1.8% during the 2nd quarter. Swiss National Bank now owns 141,100 shares of the biopharmaceutical company’s stock valued at $2,001,000 after acquiring an additional 2,500 shares in the last quarter. 63.02% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on OCUL shares. Piper Sandler restated a “buy” rating and issued a $28.00 price objective on shares of Ocular Therapeutix in a report on Friday, July 23rd. HC Wainwright upped their target price on shares of Ocular Therapeutix from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research cut Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Finally, JMP Securities reissued a “buy” rating and set a $33.00 target price on shares of Ocular Therapeutix in a research note on Friday, October 8th. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Ocular Therapeutix presently has a consensus rating of “Buy” and an average target price of $23.83.

OCUL stock traded up $0.07 during midday trading on Thursday, reaching $11.61. The stock had a trading volume of 14,263 shares, compared to its average volume of 958,208. The business has a fifty day simple moving average of $10.57 and a two-hundred day simple moving average of $13.11. The firm has a market cap of $889.13 million, a price-to-earnings ratio of -6.04 and a beta of 2.14. The company has a quick ratio of 10.00, a current ratio of 10.05 and a debt-to-equity ratio of 0.63. Ocular Therapeutix, Inc. has a twelve month low of $9.11 and a twelve month high of $24.30.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, August 9th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.09. Ocular Therapeutix had a negative net margin of 318.77% and a negative return on equity of 51.58%. The company had revenue of $11.72 million for the quarter, compared to the consensus estimate of $11.70 million. On average, equities analysts predict that Ocular Therapeutix, Inc. will post -0.59 earnings per share for the current fiscal year.

In other Ocular Therapeutix news, CEO Antony C. Mattessich purchased 5,000 shares of the stock in a transaction that occurred on Friday, August 20th. The shares were acquired at an average cost of $9.89 per share, with a total value of $49,450.00. Following the completion of the transaction, the chief executive officer now owns 102,900 shares in the company, valued at $1,017,681. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.60% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Featured Article: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.